黑料网

ISSN: 2161-119X

Otolaryngology: 黑料网
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • Otolaryngol (Sunnyvale) 2015, Vol 5(2): 185
  • DOI: 10.4172/2161-119X.1000185

Effectiveness of Second-Generation Antihistamine for the Treatment of Morning Symptoms Observed in Patients with Perennial Allergic Rhinitis: Comparison Study of Bepotastine Besilate versus Olopatadine Hydrochloride

Terumichi Fujikura1,2* and Kimihiro Okubo1
1Department of Otorhinolaryngology, Nippon Medical School, , Japan
2Department of Otolaryngology, Tokyo Woman’s Medical University Medical Center East, , Japan
*Corresponding Author : Terumichi Fujikura, Department of Otorhinolaryngology, Nippon Medical School, 1-1-5, Sendagi Bunkyo-ku, Tokyo 113-8603, Japan, Tel: +81-3-5814-6813, Fax: +81-3-5814-6914, Email: teru-fujik@nms.ac.jp

Received Date: Jan 11, 2015 / Accepted Date: Jan 25, 2015 / Published Date: Feb 02, 2015

Abstract

Objective: The aim of the present study was to examine circadian rhythm-based treatment strategies with the intension of improving the pharmacotherapy for morning symptoms with perennial allergic rhinitis. We investigated the effects of two second generation antihistamines, with different pharmacokinetic parameters, bepotastine besilate and olopatadine hydrochloride, for the treatment of morning symptoms. Methods: Twenty-four subjects with perennial allergic rhinitis were recruited for this study. They were randomly allocated to either a bepotastine group (n=10) or an olopatadine group (n=14). During the 1-hour period after waking up in the morning, the patients counted and recorded the number of sneezes and nose blowing. PNIF was also measured. The study participants took the allocated medicine twice a day. They continued recording their nasal symptoms and PNIF after awakening for 10 to 14 days. Results: In both group, taking bepotastine and olopatadine, the mean sneezing count and the mean nose blowing count were well suppressed. However, a significant change in the nasal congestion score was not observed throughout the study. Especially in olopatadine group, PNIF increased from day 2 onward and a significant increase was observed for the following 10 days. Conclusion: The worsening of nasal symptoms after awakening that is associated with perennial allergic rhinitis has a significant impact on the quality of life of patients. Two second-generation antihistamines, bepotastine besilate and olopatadine hydrochloride, were effective for the treatment of these morning symptoms. The measurement of Peak Nasal Inspiratory Flow (PNIF) value might lead to a favorable self-evaluation of nasal symptom and treatment effects. Some guidance regarding the taking of medicine from Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation the viewpoint of chronotherapy might improve the satisfaction of patients with the results of pharmacotherapy.

Keywords: Gastrointestinal tract, Antihistamine, Pharmacotherapy

Citation: Fujikura T, Okubo K (2015) Effectiveness of Second-Generation Antihistamine for the Treatment of Morning Symptoms Observed in    Patients with Perennial Allergic Rhinitis: Comparison Study of Bepotastine Besilate versus Olopatadine Hydrochloride. Otolaryngol (Sunnyvale) 5:185. Doi: 10.4172/2161-119X.1000185

Copyright: ©2015 Fujikura T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted    use, distribution, and reproduction in any medium, provided the original author and source are credited.

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top